{"entity":{"id":"kalivir-immunotherapeutics","kind":"company","name":"KaliVir Immunotherapeutics","aka":[],"tldr":"KaliVir Immunotherapeutics engineers viruses that infect and break open cancer cells while stirring an immune response. Its lead virus, VET3-TGI, is in an early trial in advanced solid tumours, alone and with the immunotherapy atezolizumab.","summary":"KaliVir Immunotherapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania; its website says its chief scientific officer co-founded it in 2019. Its Vaccinia Enhanced Template (VET) platform engineers oncolytic vaccinia viruses for systemic delivery and transgene expression in tumours. VET3-TGI expresses IL-12 and a TGF beta inhibitor and is given by intratumoural injection or intravenous infusion, alone or with atezolizumab, in the phase 1/1b STEALTH-001 trial (NCT06444815). In August 2026 the company closed a 14 million US dollar Series A extension led by Company K Partners with SV Investment and Flexus Partners, bringing the Series A to 25 million dollars. Its first registered cancer trial, NCT06444815, was posted on ClinicalTrials.gov in June 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://kalivir.com/"},{"label":"ClinicalTrials.gov: phase 1/1b STEALTH-001 trial of VET3-TGI (NCT06444815)","url":"https://clinicaltrials.gov/study/NCT06444815"},{"label":"KaliVir: 14 million dollar Series A extension (August 2026)","url":"https://kalivir.com/wp-content/uploads/2026/08/KaliVir_pr-08-19-2026_Announces-Closing-of-14-Million-Series-A-Extension-Financing.pdf"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["oncolytic-virus"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year from the company website's statement that its CSO co-founded KaliVir in 2019.","Press release of 19 August 2026 and company website read on 29 October 2026."],"hq":"Pittsburgh, PA","country":"US","companyType":"biotech","website":"https://kalivir.com/","founded":2019,"stage":"startup","investors":[],"funding":[{"round":"Series A extension","year":2026,"amountUsd":14000000,"source":"https://kalivir.com/wp-content/uploads/2026/08/KaliVir_pr-08-19-2026_Announces-Closing-of-14-Million-Series-A-Extension-Financing.pdf","note":"Led by Company K Partners with SV Investment, Flexus Partners and existing investors including affiliates of Nextrans and Quad Investment Management; total Series A 25 million US dollars."}]},"route":"/companies/kalivir-immunotherapeutics/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"oncolytic-virus","kind":"technology","name":"Oncolytic viruses","route":"/technologies/oncolytic-virus/"}]}}